Tunjic Tin M, Weber Noah, Brunsteiner Michael
Celeris Therapeutics GmbH, Schmiedlstraße 3, 8042 Graz, Austria.
Comput Struct Biotechnol J. 2023 Feb 24;21:2058-2067. doi: 10.1016/j.csbj.2023.02.042. eCollection 2023.
Proteolysis targeting chimeras represent a class of drug molecules with a number of attractive properties, most notably a potential to work for targets that, so far, have been in-accessible for conventional small molecule inhibitors. Due to their different mechanism of action, and physico-chemical properties, many of the methods that have been designed and applied for computer aided design of traditional small molecule drugs are not applicable for proteolysis targeting chimeras. Here we review recent developments in this field focusing on three aspects: de-novo linker-design, estimation of absorption for beyond-rule-of-5 compounds, and the generation and ranking of ternary complex structures. In spite of this field still being young, we find that a good number of models and algorithms are available, with the potential to assist the design of such compounds in-silico, and accelerate applied pharmaceutical research.
靶向嵌合体蛋白酶解物代表了一类具有许多吸引人特性的药物分子,最显著的是它们有可能作用于迄今传统小分子抑制剂无法作用的靶点。由于其不同的作用机制和物理化学性质,许多为传统小分子药物的计算机辅助设计而设计和应用的方法并不适用于靶向嵌合体蛋白酶解物。在此,我们综述该领域的最新进展,重点关注三个方面:从头设计连接子、评估超过五规则化合物的吸收情况以及三元复合物结构的生成和排序。尽管该领域仍处于起步阶段,但我们发现已有大量模型和算法,有潜力在计算机辅助下协助此类化合物的设计,并加速应用药物研究。